Literature DB >> 26097538

Expression of MMP14 in invasive pituitary adenomas: relationship to invasion and angiogenesis.

Pinjing Hui1, Xu Xu2, Lan Xu2, Guozhen Hui3, Shiliang Wu2, Qing Lan4.   

Abstract

Pituitary adenomas (PAs) are noncancerous tumors, and about 35% of those reported to be invasive have been classified as "invasive pituitary adenomas (IPAs)". In clinical, operative complications, total resection failures, and high relapse rates result from invasive features during the therapeutic process. Invasive mechanism is a complex process, including metalloproteases, inhibitors and tumor microenvironment factors etc. Thus, studying invasive mechanism of PAs might contribute to understanding its biological behavior. In our research, three type tissue samples of human, pituitaries, PAs, IPAs, their mRNA expression of MMP1, MMP2, MMP9, MMP14 and MMP15 were measured using real-time PCR. MMP2 and MMP14 protein levels also were measured with immunohistochemistry in same samples. We confirmed that elevated matrix metalloproteinase-14 expression correlates with invasive characteristics of IPAs. To investigate molecular mechanism of how MMP14 contributes to invasiveness, an ATT20 cell was used in this study. After transient-transfection of the MMP14-shRNA expression vector into ATT20 cells, we observed that mRNA expression of PTTG, VEGF, and TGFβ was significantly suppressed in interference groups. Meanwhile, ATT20 cells in high concentration TIMP-1 environment exhibit reduced PTTG, VEGF, and TGFβ expression accompanied with the down-regulation of MMP14. Thus, we propose that MMP14 plays an important role in tumor invasion and angiogenesis and that a novel regulatory pathway for MMP14 may exist through VEGF and PTTG. In brief, MMP14 may be a target for therapeutic treatment.

Entities:  

Keywords:  ATT20; MMP14; PTTG; VEGF; invasive pituitary adenomas

Mesh:

Substances:

Year:  2015        PMID: 26097538      PMCID: PMC4466925     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  32 in total

1.  Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis.

Authors:  Elena I Deryugina; Liliana Soroceanu; Alex Y Strongin
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

2.  A decade of pituitary microsurgery. The Herbert Olivecrona lecture.

Authors:  C B Wilson
Journal:  J Neurosurg       Date:  1984-11       Impact factor: 5.115

3.  An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature.

Authors:  Kaisa Lehti; Edward Allen; Henning Birkedal-Hansen; Kenn Holmbeck; Yasuhiro Miyake; Tae-Hwa Chun; Stephen J Weiss
Journal:  Genes Dev       Date:  2005-04-01       Impact factor: 11.361

Review 4.  Management of pituitary tumors in pregnancy.

Authors:  Marcello D Bronstein; Diane B Paraiba; Raquel S Jallad
Journal:  Nat Rev Endocrinol       Date:  2011-03-15       Impact factor: 43.330

5.  The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas.

Authors:  J A C Hunter; R H Skelly; S J B Aylwin; J F Geddes; J Evanson; G M Besser; J P Monson; J M Burrin
Journal:  Eur J Endocrinol       Date:  2003-02       Impact factor: 6.664

6.  Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis.

Authors:  D C Martin; O H Sanchez-Sweatman; A T Ho; D S Inderdeo; M S Tsao; R Khokha
Journal:  Lab Invest       Date:  1999-02       Impact factor: 5.662

7.  Management of large aggressive nonfunctional pituitary tumors: experimental medical options when surgery and radiation fail.

Authors:  Brandon A Miller; W Caleb Rutledge; Adriana G Ioachimescu; Nelson M Oyesiku
Journal:  Neurosurg Clin N Am       Date:  2012-10       Impact factor: 2.509

8.  Internal carotid arterial shift after transsphenoidal surgery in pituitary adenomas with cavernous sinus invasion.

Authors:  Yasuo Sasagawa; Osamu Tachibana; Mariko Doai; Takuya Akai; Hisao Tonami; Hideaki Iizuka
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

9.  Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP.

Authors:  Farideh Sabeh; Ichiro Ota; Kenn Holmbeck; Henning Birkedal-Hansen; Paul Soloway; Milagros Balbin; Carlos Lopez-Otin; Steven Shapiro; Masaki Inada; Stephen Krane; Edward Allen; Duane Chung; Stephen J Weiss
Journal:  J Cell Biol       Date:  2004-11-22       Impact factor: 10.539

10.  Critical role of transient activity of MT1-MMP for ECM degradation in invadopodia.

Authors:  Ayako Watanabe; Daisuke Hoshino; Daisuke Hosino; Naohiko Koshikawa; Motoharu Seiki; Takashi Suzuki; Kazuhisa Ichikawa
Journal:  PLoS Comput Biol       Date:  2013-05-30       Impact factor: 4.475

View more
  13 in total

1.  MMP-14 and TGFβ-1 methylation in pituitary adenomas.

Authors:  Kornelija Ruskyte; Rasa Liutkevicienė; Alvita Vilkeviciute; Paulina Vaitkiene; Indre Valiulytė; Brigita Glebauskiene; Loresa Kriauciuniene; Dalia Zaliuniene
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

2.  The Pituitary Tumors and Their Tumor-Specific Microenvironment.

Authors:  M M Kameda-Smith; J -Q Lu
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  MicroRNA-145 inhibits the activation of the mTOR signaling pathway to suppress the proliferation and invasion of invasive pituitary adenoma cells by targeting AKT3 in vivo and in vitro.

Authors:  Kai Zhou; Yan-Dong Fan; Peng-Fei Wu; Serick Duysenbi; Zhao-Hai Feng; Guo-Jia Du; Ting-Rong Zhang
Journal:  Onco Targets Ther       Date:  2017-03-16       Impact factor: 4.147

4.  HOXC6 promotes migration, invasion and proliferation of esophageal squamous cell carcinoma cells via modulating expression of genes involved in malignant phenotypes.

Authors:  Li Tang; Yong Cao; Xueqin Song; Xiaoyan Wang; Yan Li; Minglan Yu; Mingying Li; Xu Liu; Fang Huang; Feng Chen; Haisu Wan
Journal:  PeerJ       Date:  2019-03-14       Impact factor: 2.984

Review 5.  Molecular Network Basis of Invasive Pituitary Adenoma: A Review.

Authors:  Qi Yang; Xuejun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-24       Impact factor: 5.555

Review 6.  Matrix metalloproteinase-9 and -2 and tissue inhibitor of matrix metalloproteinase-2 in invasive pituitary adenomas: A systematic review and meta-analysis of case-control trials.

Authors:  Hong-Yan Liu; Wei-Jun Gu; Cheng-Zhi Wang; Xiao-Jian Ji; Yi-Ming Mu
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

Review 7.  The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.

Authors:  Giovanni Barillari; Paolo Monini; Cecilia Sgadari; Barbara Ensoli
Journal:  Int J Mol Sci       Date:  2018-05-09       Impact factor: 5.923

Review 8.  Recent advances in understanding corticotroph pituitary tumor initiation and progression.

Authors:  Ulrich Renner; Denis Ciato; Günter K Stalla
Journal:  F1000Res       Date:  2018-08-29

Review 9.  Angioregulatory microRNAs in Colorectal Cancer.

Authors:  Mohammad Hasan Soheilifar; Michael Grusch; Hoda Keshmiri Neghab; Razieh Amini; Hamid Maadi; Massoud Saidijam; Zhixiang Wang
Journal:  Cancers (Basel)       Date:  2019-12-26       Impact factor: 6.639

10.  Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: A model for studying atherogenic mechanisms.

Authors:  Emily R Bowman; Cheryl M Cameron; Brian Richardson; Manjusha Kulkarni; Janelle Gabriel; Morgan J Cichon; Kenneth M Riedl; Yousef Mustafa; Michael Cartwright; Brandon Snyder; Subha V Raman; David A Zidar; Susan L Koletar; Martin P Playford; Nehal N Mehta; Scott F Sieg; Michael L Freeman; Michael M Lederman; Mark J Cameron; Nicholas T Funderburg
Journal:  PLoS Pathog       Date:  2020-10-01       Impact factor: 7.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.